ClinicalTrials.Veeva

Menu

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Not yet enrolling
Phase 2

Conditions

Dermatitis, Atopic

Treatments

Drug: GSK1070806

Study type

Interventional

Funder types

Industry

Identifiers

NCT06447506
2023-508474-29-00 (Other Identifier)
220723

Details and patient eligibility

About

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

Enrollment

158 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants must sign and date the consent document.
  • Participants diagnosed with moderate to severe Atopic dermatitis (AtD) who have completed the qualifying Phase 2 parent study (NCT05999799) of GlaxoSmithKline (GSK's) AtD and, in their opinion, may benefit from GSK1070806.
  • Be intentional and able to visit the doctor at the clinic by appointment and follow all procedures related to research studies and questionnaires (able to read and understand Patient-reported outcomes (PRO) questionnaires and be able to use electronic devices).
  • The use of contraceptive methods for females should be consistent with local regulations on contraceptive methods of participants participating in clinical research programs.
  • Female participants are eligible to participate in the research program if they are not pregnant or breastfeeding and meet one of the following conditions:
  • It is Woman of nonchildbearing potential (WONCBP).
  • It is Woman of childbearing potential (WOCBP) and uses a highly effective contraceptive method that has a failure rate less than (<) 1 percent (%) during the trial dose period and for at least 16 weeks after the last dose of the research drug. We should assess the likelihood of contraceptive failure (e.g., non-cooperation, early contraception) associated with the first dose of the drug.
  • WOCBP must obtain a negative result in a highly sensitive pregnancy test (by urine or serum test, as prescribed by local regulations) before receiving the first dose of the research drug.
  • If the urine test is positive, or the negative result cannot be confirmed (i.e., the result is unclear), a pregnancy test by serum test is required. In such cases, If the serum is tested, the test result is positive. Participants must be excluded from the research project.
  • Additional requirements for testing pregnancy during and after exposure to the drug.
  • The researcher is responsible for examining medical history, menstrual cycle history, and sexual activity in the near term. To reduce the risk of screening pregnant women who may not be detected at the beginning of pregnancy.

Exclusion criteria

  • Permanent discontinuation of the study drug at any time during GSK's qualifying Phase 2 AtD (NCT05999799) or a medical condition that would hinder GSK's participation in the Phase 2 219538 (NCT05999799) AtD research project.
  • Participants who, during GSK's qualifying Phase 2 (NCT05999799) AtD research project, developed adverse event (AE) or Serious adverse event (SAE) based on laboratory parameters, physical examination, vital signs, Electrocardiogram (ECG), medical history, etc. Medical history, in the opinion of the researchers, suggests that if Investigational medicinal product (IMP) is continued, it may cause unnecessary risk to the participants.
  • Topical medications for AtD within 1 week prior to your appointment at Day 1, such as: Topical calcineurin inhibitors (TCI)/ Topical corticosteroids (TCS), Phosphodiesterase-4 (PDE-4) and Janus activation kinase inhibitors (JAKi) for external use.
  • Topical corticosteroids (TCS) (such as hydrocortisone, betamethasone)
  • Topical calcineurin inhibitors (TCI) (such as tacrolimus, pimecrolimus)
  • Phosphodiesterase-4 (PDE4) inhibitor for external use (e.g., crisaborole)
  • JAKi for external use (e.g. ruxolitinib)
  • Medications for topical use, or other herbal/traditional medicines that may affect the AtD that the participants are in.
  • Participant who received systemic therapy, which is considered contraindicated, including systemic therapy used as a rescue medication for AtD, from the screening for GSK's Phase 2 AtD 219538 research project until the LTE protocol began, were unable to participate in the research project.
  • Chronic uncontrolled diseases that may require immediate oral corticosteroids, such as severe uncontrolled asthma (defined as having an Asthma control questionnaire (ACQ)-5 score greater than or equal to (>=) of 1.5 or a history of asthma exacerbations. >= 2 times within the last 12 months, requiring systemic corticosteroid [oral and/or intravenous medication] or requiring a >-24-hour hospital stay)
  • Experience participating in previous/current clinical research projects.
  • The participants have participated in any other clinical research studies. This is in addition to GSK's Phase 2 219538 (NCT05999799) research project.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

158 participants in 4 patient groups

GSK1070806 Dose 1
Experimental group
Description:
Participants will receive GSK1070806 Dose 1.
Treatment:
Drug: GSK1070806
GSK1070806 Dose 2
Experimental group
Description:
Participants will receive GSK1070806 Dose 2.
Treatment:
Drug: GSK1070806
GSK1070806 Dose 3
Experimental group
Description:
Participants will receive GSK1070806 Dose 3.
Treatment:
Drug: GSK1070806
GSK1070806 Dose 4
Experimental group
Description:
Participants will receive GSK1070806 Dose 4.
Treatment:
Drug: GSK1070806

Trial contacts and locations

91

Loading...

Central trial contact

EU GSK Clinical Trials Call Center; US GSK Clinical Trials Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems